XML 24 R14.htm IDEA: XBRL DOCUMENT
v3.23.3

Accounts Payable and Accrued Liabilities | 9 Months Ended
--- | ---
Sep. 30, 2023
Payables and Accruals [Abstract] |
Accounts Payable and Accrued Liabilities | Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consisted of the following:
(in millions) | September 30, 2023 |  | December 31, 2022
Sales rebates and reserves | $ | 184.0 |  |  | $ | 131.9 |
Income taxes payable | 72.7 |  |  | 9.0 |
Accrued employee related costs | 68.6 |  |  | 72.8 |
Current branded prescription drug fee | 44.5 |  |  | 27.5 |
Accrued development costs | 39.5 |  |  | 39.1 |
Accounts payable and other accrued liabilities | 93.8 |  |  | 67.3 |
Total accounts payable and accrued liabilities | $ | 503.0 |  |  | $ | 347.6 |

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration